Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG-Reference-Cited by-同舟云学术

Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG

Published:2018-02 Issue: Volume:122 Page:144-149
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Beauval Jean-Baptiste,Loriot Yohann,Hennequin Christophe,Rozet François,Barthelemy Philippe,Borchiellini Delphine,Schlürmann Constans Friederike,Gross Emmanuel,Maillet Denis,Pasticier Gilles,Pignot Géraldine,Timsit Marc-Olivier,Vincendeau Sébastien,Ploussard Guillaume,Sargos Paul

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference50 articles.

1. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients;Afshar-Oromieh;Eur. J. Nucl. Med. Mol. Imaging,2017

2. Global Cancer Facts and Figs.;American Cancer Society,2015

3. Approach to oligometastatic prostate cancer;Bernard;Am. Soc. Clin. Oncol. Educ. Book,2016

4. May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?;Botticella;J. Cancer Res. Clin. Oncol.,2013

5. Selective lymph node dissection for castration-resistant prostate cancer;Busch;Urol. Int.,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance;Progrès en Urologie;2022-11

2. Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer;Frontiers in Cell and Developmental Biology;2022-08-12

3. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?;Progrès en Urologie;2022-06

4. Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts;Radiotherapy and Oncology;2022-05

5. La chirurgie dans le cancer de prostate oligo-métastatique a-t-elle une place dans la prise en charge de nos patients ?;Progrès en Urologie - FMC;2021-09